drugset / Trial / NCT01196039

A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)

NCT01196039 ↗

Phase 2 Completed 29 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the treatment of allergen-induced asthma.

Timeline

Start
2010-12
Primary completion
2011-08
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quilizumab Monoclonal antibody — Intravenous

Indications